About Agile Therapeutics
Agile Therapeutics is a healthcare company that focuses on women's health. The company offers contraceptive options that provide an alternative to daily pills, utilizing their proprietary transdermal patch technology, Skinfusion®, for drug delivery through the skin. Agile Therapeutics primarily serves the healthcare industry, specifically the women's health sector. It was founded in 1997 and is based in Princeton, New Jersey.
Agile Therapeutics Patents
Agile Therapeutics has filed 33 patents.
Diabetes, Routes of administration, Euphoriants, Dosage forms, Drug delivery devices
Diabetes, Routes of administration, Euphoriants, Dosage forms, Drug delivery devices
Latest Agile Therapeutics News
Feb 15, 2024
Agile Therapeutics, Inc. Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022 GAAP Operating Expenses for Full Year 2023 Expected to be in the Range of $30 to $31.5 Million, a Decrease of 47% to 44% Compared to Full Year 2022 PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced it has been granted an extension by Nasdaq to regain compliance with the stockholders’ equity requirement for continued listing and provided performance update for full year 2023. Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement On February 13, 2024, the Company received a letter from the Hearings Panel (“Panel”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it has been granted an additional period, or until March 25, 2024, to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000. The Company had previously presented its plan to the Panel and is continuing to proceed with initiatives to regain compliance within the extension granted. Expected Full Year 2023 Performance Update (Unaudited) The Company also announced its preliminary expectations for net revenue and operating expenses for the full year 2023. Full year 2023 net revenue is expected to be in the range of $20 to $21 million compared to $10.9 million for the full year 2022, representing an increase of 84% to 93%. Full year 2023 GAAP operating expenses (“OPEX”) are expected to be in the range of $30 to $31.5 million compared to $56.6 million for the full year 2022, representing a decrease of 47% to 44%. Management has recommended to the Board of Directors, that the Company not pay performance bonuses for the 2023 fiscal year. As a result, the Company plans to reverse an accrual of approximately $2.1 million. The preliminary results and estimates in this press release are based on management’s initial review of our operations for the fiscal year ended December 31, 2023, and are subject to revision based upon our quarter-end and year-end closing procedures and the completion of the external audit of our year-end financial statements. About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website and LinkedIn account. Forward-Looking Statements Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our financial condition, our ability to repay our debt to Perceptive, our expected net revenue and expected operating expenses for fiscal year 2023, and our ability to regain compliance with Nasdaq continued listing requirements and continue trading on the Nasdaq Capital Market. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to raise enough capital to fund our operations in the near term and long term, including our ability to obtain funding through public or private equity offerings, debt financings or other sources, on terms acceptable to us or at all, our ability to come into and maintain compliance with the Nasdaq Capital Market listing requirements, the potential de-listing of our shares on the Nasdaq Capital Market, our ability to continue to commercialize and grow Twirla the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, please refer to our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. Contact:
Agile Therapeutics Frequently Asked Questions (FAQ)
When was Agile Therapeutics founded?
Agile Therapeutics was founded in 1997.
Where is Agile Therapeutics's headquarters?
Agile Therapeutics's headquarters is located at 101 Poor Farm Road, Princeton.
What is Agile Therapeutics's latest funding round?
Agile Therapeutics's latest funding round is IPO.
How much did Agile Therapeutics raise?
Agile Therapeutics raised a total of $124.55M.
Who are the investors of Agile Therapeutics?
Investors of Agile Therapeutics include Care Capital, Investor Growth Capital, Aisling Capital, Novitas Capital, ProQuest Investments and 5 more.
Who are Agile Therapeutics's competitors?
Competitors of Agile Therapeutics include Aphios, Dicerna Pharmaceuticals, PhaseRx, Biodel, Jennerex Biotherapeutics and 7 more.
Compare Agile Therapeutics to Competitors
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Respirics Inc. is a pulmonary drug delivery and development company located in Raleigh, North Carolina. The company is developing a line of branded inhalation drug products in its patented Acu-Breathe™ dry powder inhalers, and is working with pharmaceutical clients to enhance the delivery of their own compounds or formulations. Respirics combines proprietary inhalation technology with powder drug formulation expertise to develop unique drug delivery solutions. The company is committed to bringing effective, easy-to-use and affordable inhalation drug products to the patients who need them.
REGiMMUNE is a biotechnology company focused on the development of novel medicines for immune disorders. The company's main offerings include treatments designed to modulate the immune system and harness a patient's own immune response for inducing tolerance and achieving anti-tumor effects. These therapies are aimed at a range of immune-related conditions. It was founded in 2006 and is based in Tokyo, Japan.
Millennium Cryogenics specializes in the preservation and storage of biological samples within the biotechnology sector. The company offers cryopreservation services using liquid nitrogen to maintain samples at controlled temperatures for long-term storage. These services cater to entities that require reliable backup storage for mission-critical biological specimens. It is based in Athens, Georgia.
WesaGen is a biopharmaceutical company founded by Dr.Mustapha Abdelouahed, Ph.D., with expertise in Immunology, Hemostasis, Coagulation, Cell & Molecular Biology of Vessels, and Dr. Jack Lawler, Ph.D., Professor at Harvard Medical School. WesaGen is engaged in the near-term development of technologies to diagnose type 2 heparin-induced thrombocytopenia (or HIT, a life-threatening condition); the development of a line of and potent anti-angiogenic therapeutic drugs to treat cancer; and research and development based on a new nanoscale drug delivery platform technology.
Oligomerix is a biotechnology company that focuses on the development of disease-modifying therapeutics for neurodegenerative diseases, specifically those characterized by aberrant tau protein. The company's main offerings include small molecule inhibitors that target the tau aggregation cascade and its progression, aiming to treat conditions ranging from rare tauopathies to Alzheimer's disease. The company primarily serves the healthcare sector, particularly in the area of neurodegenerative diseases. It was founded in 2006 and is based in West Harrison, New York.